douglas-pharma-and-uwa-join-hands-for-developing-new-cancer-therapies
Category: #health  By Saipriya Iyer  Date: 2018-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

douglas-pharma-and-uwa-join-hands-for-developing-new-cancer-therapies

Douglas Pharmaceuticals Limited, a key pharma product manufacturer headquartered in New Zealand, has signed a partnership deal with The University of Western Australia (UWA) & Telethon Kids Institute for developing new cancer immunotherapies. Reportedly, Dr. Joost Lesterhuis, a leading cancer researcher & group leader at the UWA, along with his team, has utilized network analysis procedure to study how genes are connected with one another in any cancer type and how they can be activated for responding favorably towards the cancer immunotherapy.

Apparently, the research group has concluded that the medicine combinations will help activate the genes, thereby acquiring positive outcomes post immunotherapy. The deal is expected to help the scientists at UWA develop such drug combinations in collaboration with Douglas Pharma, ultimately aiming toward a clinical trial by next year.

According to Dr. Joost, the alliance will generate a new opportunity for both the organizations to transform their research into clinical data that will assist in coining effective methods for cancer treatment. He has further stated that the association will help in performing vital lab studies and understand why some of the subjects respond positively to cancer immunotherapy while some others do not.

Jeff Douglas, the MD of Douglas Pharmaceuticals, is of the view that the strategic move will help in converting cancer research activities into the development of smart drugs for improving treatment in cancer patients that do not respond favorably to the existing therapies. Dr. Lesterhuis is of the view that the myriad approaches from unrelated fields such as cancer medicine, mathematics, and computer science can provide the researchers with unique insights into cancer treatments.

One of the researchers working under the auspices of Joost has remarked that the partnership will help in creating a new approach that can determine new as well as safe combinations of the authorized drugs that can benefit cancer subjects, thereby propelling its therapeutic uses across the cancer therapy sector.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...